Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Pediatr Res ; 84(1): 66-70, 2018 07.
Article in English | MEDLINE | ID: mdl-29795204

ABSTRACT

BACKGROUND: We investigated 'rare' bile acids (BA) as potential markers in septic neonates. METHODS: 'Rare' (C-6 hydroxylated BA) and 'classical' BA were determined in 102 neonates using high-performance liquid chromatography-high-resolution mass spectrometry (HPLC-HRMS). Four groups according to maturity (full term, FT vs. preterm, PT) and septic status (early-onset neonatal sepsis, EOS vs. CTR; non-septic controls) were formed: FT-CTR; (n = 47), PT-CTR (n = 22), FT-EOS (n = 20), PT-EOS (n = 13). RESULTS: Firstly, FT-CTR had a significant higher amount of 'rare' BA than PT (FT-CTR: 0.5 µmol/L, IQR: 0.3-1.3 vs. PT-CTR: 0.01 µmol/L, IQR 0.01-0.2; p < 0.01). The most common 'rare' BA in FT-CTR were tauro-γ- (TGMCA) and tauro-α-muricholic acid (TAMCA). Secondly, in EOS, absolute 'rare' BA levels were comparable in both gestational age groups (FT-EOS: 0.6 µmol/L, IQR: 0.1-1.6 and PT-EOS: 0.6 µmol/L, IQR: 0.2-1.5). Therefore, EOS had significantly higher median 'rare' BA values than non-septic PT neonates (p < 0.01). In PT and term neonates, the relative amount of tauro-ω-muricholic acid (TOMCA) within the 'rare' BA pool was significantly higher in EOS than in controls (FT-CTR vs. "FT-EOS and PT-CTR vs. PT-EOS; p < 0.01). It was hence the predominant 'rare' BA in EOS. CONCLUSION: TOMCA is an independent factor associated with EOS. It has diagnostic potential.


Subject(s)
Bile Acids and Salts/blood , Biomarkers/blood , Neonatal Sepsis/blood , Taurocholic Acid/analogs & derivatives , Chromatography, High Pressure Liquid , Female , Gestational Age , Humans , Infant, Newborn , Infant, Premature , Male , Mass Spectrometry , Prospective Studies , Taurocholic Acid/blood
2.
Anticancer Res ; 29(6): 1951-61, 2009 Jun.
Article in English | MEDLINE | ID: mdl-19528452

ABSTRACT

Carcinoids are rare tumors derived from enterochromaffin (EC) cells of the embryonic neural crest. They have malignant potential and their incidence is steadily increasing. The only curative treatment option is surgery. We have focused on cultivation of human neuroendocrine tumors (NET) as relevant models for the study of potential therapy. Only a few cell lines from human carcinoids have been established so far, among them our earlier KRJ-I cell line from a human ileal carcinoid. The reason for the poor success in establishing carcinoid cell lines is due to the small amount of tissue available and the low mitotic activity in primary cultures. We have successfully established three continuously growing cell lines from tissue obtained from a metastatic human carcinoid of the terminal ileum (midgut carcinoid): P-STS was derived from the primary tumor, L-STS from a lymph node metastasis and H-STS from a hepatic metastasis. Immunocytochemistry proved the maintenance of characteristic neuroendocrine properties. Electron microscopy confirmed the presence of neuroendocrine granules. The three cell lines were tumorigenous in SCID-mice. Cytogenetic analyses revealed clonal tetraploidy, inversion and deletion in chromosome 18q, and non-clonal numerical and structural aberrations. Array CGH did not show notable imbalances. Mutation screening of P-STS excluded a MEN1-gene-associated genetic predisposition with high probability. The novel cell lines P-STS, L-STS and H-STS may be useful in vitro and in vivo models for further studies of biological characteristics and the development of new therapeutic agents.


Subject(s)
Carcinoid Tumor/pathology , Enterochromaffin Cells/pathology , Ileal Neoplasms/pathology , Lung Neoplasms/secondary , Adult , Animals , Carcinoid Tumor/genetics , Carcinoid Tumor/metabolism , Chromosomes, Human, Pair 18/genetics , Comparative Genomic Hybridization , Cryopreservation , Female , Humans , Ileal Neoplasms/genetics , Ileal Neoplasms/metabolism , Immunoenzyme Techniques , Lung Neoplasms/genetics , Lung Neoplasms/metabolism , Lymphatic Metastasis , Male , Mice , Mice, SCID , Mutation/genetics , Oligonucleotide Array Sequence Analysis , Ploidies , Proto-Oncogene Proteins/genetics , Tumor Cells, Cultured , Xenograft Model Antitumor Assays
3.
Biologics ; 1(4): 455-63, 2007 Dec.
Article in English | MEDLINE | ID: mdl-19707315

ABSTRACT

Medullary thyroid carcinoma (MTC), a neuroendocrine tumor arising from the thyroid gland, is known to be poorly responsive to conventional chemotherapy. The root of Stemona tuberosa Lour, also called Bai Bu, is a commonly used traditional Chinese anti-tussive medicine. The present study investigated this medicinal herb for the first time with respect to its anticancer activity in human medullary thyroid carcinoma cells. Four extracts of Stemona tuberosa Lour, including the n-hexane fraction, (ST-1), dichloromethane (DCM) fraction, (ST-2), ethyl acetate (EtOAc) fraction, (ST-3), and methanol fraction, (ST-4) were examined for antiproliferative effects in two MTC cell lines. We observed that only the DCM fraction ST-2 inhibited cell growth and viability in a dose-dependent manner. Furthermore, we found that ST-2 also induced the apoptosis of MTC-SK cells. Caspase-3/7 was activated, while caspase-9 was not, implying that at least a caspase-dependent apoptotic pathway was involved in this process. In addition, the multicellular spheroids of MTC-SK were destroyed and the cell morphology was changed by ST-2. Our results show the strong apoptotic effects of the DCM fraction of Stemona tuberosa Lour on human medullary thyroid carcinomas, so suggesting a new candidate for chemotherapy of the so far chemo-resistant medullary thyroid carcinoma.

SELECTION OF CITATIONS
SEARCH DETAIL
...